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Metformin has a distinct advantage of lowering serum glucose levels without causing hyper-insulinemia and subsequent risk of hypoglycemia, or weight gain. 1.3 In order to find a substance that enhances the therapeutic effects of metformin, and exhibits additional pancreas-protecting effects, we synthesized the title compound. In this paper, we report on the synthesis and crystal structure of the compound 1.
An ethanolic solution (5 ml) of ethyl N-(3-tossulfonyl)-carbamate (4 mmol), which can be easily obtained, 2 was added to an ethanolic solution (5 ml) of metformin (1 mmol), which was prepared according to a modified method from the literature. 3 The solution was stirred for 3 h at room temperature. and then allowed to stand at room temperature for one night. Subsequently, colourless block-shaped crystals, suitable for Xray diffraction, were obtained from the solution.
A colorless crystal having dimensions of 0.31 ¥ 0.26 ¥ 0.25 mm was chosen for X-ray diffraction studies. Measurements were made on a BRUKER SMART 1000 CCD diffractometer equipped with graphite crystal monochromatized Mo Ka radiation (l = 0.71073 Å) at 293(2)K. The structure was solved by direct methods with the SHELX-97 program, and expanded with a difference Fourier technique. The non-hydrogen atoms were refined anisotropically by the full-matrix least-squares method based on F 2 with all observed reflections. The hydrogen atoms were generated geometrically with isotropic thermal parameters. The experimental crystallographic details are given in Table 1 . An ORTEP plot of the title compound is shown in Fig. 2 . Figure 3 represents the hydrogen-bonding interactions of the title compound. Selected bond lengths and angles are summarized in Table 2 . The hydrogen-bonding distances and angles are presented in Table 3 .
Compound 1 crystallizes in space group P1. As shown in Fig.  1 , the formation of the anion of ethyl N-(3-tossulfonyl)carbamate results from a single proton transfer from ethyl N-(3-tossulfonyl)carbamate to metformin. This can be because the conjugative effect steadies the structure. As can be seen from conformations of the metformin have two different forms: one is the -C(NH2)2 group, which is near to the -N(CH3)2 group; another one is the -C(NH2)2 group, which is apart from the -N(CH3)2 group. 5 In the title compound, the -C(NH2)2 group is near to the -N(CH3)2 group with the N6-C12-N4-C11 dihedral angle [-77 .11(0.24)˚], which is wider than the reported dihedral angle (-53.7˚). 5 This can be attributed to the intermolecular hydrogen bonds between metformin and ethyl N-(3-tossulfonyl)carbamate. The average S=O bond length (1.4449 Å), C=N bond length (1.344 Å) and the C-N bond length (1.461 Å) conform to the usually observed values. However, the distance of N-S is 1.5826(15)Å, which is shorter than the typical value for a single bond (1.60 -1.64 Å) because of the conjugative effect. 4 The crystal of 1 is stabilized by two kinds of intermolecular hydrogen bonds (N-H·O, N-H·N) involving the -NH2, =NH2 + functions of metformin, and the oxygen atoms, nitrogen atoms of carbamate, as showen in Table 4 . As a result, a large twodimensional molecular network is constructed from the metformin and the ethyl N-(3-tossulfonyl) carbamate molecules via intermolecular N=H·O, N=H·N interactions, as shown in Fig. 3 . Table 2 Selected bond lengths (Å) and angles (˚) 
